Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
Rhea-AI Summary
Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £620,000 in funding through the issuance of convertible loan notes (CLNs) to support its ongoing clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.
The CLNs were issued at a fixed conversion price of £5.30 per share and are non-interest bearing. They will automatically convert into 116,982 Ordinary Shares following an increase in the Company's headroom restrictions under FCA's Prospectus Rules, expected around November 15, 2025.
Positive
- Secured £620,000 in additional funding for clinical trial development
- Non-interest bearing CLNs minimize debt service costs
- Fixed conversion price at £5.30 provides price stability
- Funding demonstrates investor confidence in HG-CT-1 clinical trial progress
Negative
- Future dilution of existing shareholders upon CLN conversion
- Relatively small funding amount may indicate limited investor interest
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Issue of convertible loan notes to raise
LONDON, GB / ACCESS Newswire / September 1, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised
Convertible Loan Notes
To support the clinical trial, the Company has raised
The CLNs, which are non-interest bearing, will automatically convert following an increase in the Company's headroom restrictions under the FCA's Prospectus Rules, allowing for the issuance of conversion shares without requiring an approved prospectus. This conversion is expected to take place on or after 15 November 2025.
Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, commented:
"We are very encouraged by the progress of our Phase I clinical trial of HG-CT-1, and we are grateful for the continued support of our investors. Their participation in this funding reflects confidence in our strategy and long-term vision. These CLNs strengthen our balance sheet, extend our financial runway, and enable us to maintain momentum in the clinical development of HG-CT-1 for patients with relapsed or refractory acute myeloid leukemia."
Application for Admission
The Company will apply for the admission of the 116,982 Ordinary Shares, issued to subscribers upon the conversion of the CLNs, to trading on the London Stock Exchange. Admission is expected to become effective after 15 November 2025.
Upon admission, the new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares and will be entitled to receive all future dividends and distributions declared, paid, or made on the Company's ordinary share capital.
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | ||
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | ||
Peter Redmond, Director | ||
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | |
Matthew Johnson, Vadim Alexandre, Adam Cowl | ||
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 | |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City .
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
How much funding did Hemogenyx Pharmaceuticals (HOPHF) raise through convertible loan notes in September 2025?
What is the conversion price for Hemogenyx's September 2025 convertible loan notes?
When will Hemogenyx's September 2025 convertible loan notes convert to shares?
What will Hemogenyx use the September 2025 convertible loan note proceeds for?
How many new shares will be issued when Hemogenyx's convertible notes convert?
